Testing a new gene-silencing treatment for rare childhood brain disorder

This is the first human trial of Tianasen, a personalized medication designed to treat children with a rare genetic condition called GNAO1-encephalopathy that causes seizures and involuntary movement disorders. Tianasen works by silencing the faulty gene responsible for the disease, allowing the body to stop making the harmful protein that damages the brain. The trial will test whether this approach is safe and whether it can slow or improve the symptoms of this serious childhood illness.

GNAO1-encephalopathy is a severe, progressive disorder with no approved treatments—children currently receive only medications to manage symptoms, not to address the underlying cause. This medication offers a new hope by directly targeting the genetic flaw, potentially changing the natural course of the disease for children who have already tried multiple seizure and movement medications without success.